These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1212 related items for PubMed ID: 27386769

  • 1. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
    Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP, Lenihan DJ, Gottlieb SS, Shah SJ, Steidley DE, Ventura H, Murali S, Silver MA, Jacoby D, Fedson S, Hummel SL, Kristen AV, Damy T, Planté-Bordeneuve V, Coelho T, Mundayat R, Suhr OB, Waddington Cruz M, Rapezzi C, THAOS Investigators.
    J Am Coll Cardiol; 2016 Jul 12; 68(2):161-72. PubMed ID: 27386769
    [Abstract] [Full Text] [Related]

  • 2. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis.
    Coelho T, Maurer MS, Suhr OB.
    Curr Med Res Opin; 2013 Jan 12; 29(1):63-76. PubMed ID: 23193944
    [Abstract] [Full Text] [Related]

  • 3. A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
    Gentile L, Coelho T, Dispenzieri A, Conceição I, Waddington-Cruz M, Kristen A, Wixner J, Diemberger I, Gonzalez-Moreno J, Cariou E, Maurer MS, Planté-Bordeneuve V, Garcia-Pavia P, Tournev I, Gonzalez-Costello J, Duarte AG, Grogan M, Mazzeo A, Chapman D, Gupta P, Glass O, Amass L, THAOS investigators.
    Orphanet J Rare Dis; 2023 Nov 10; 18(1):350. PubMed ID: 37946256
    [Abstract] [Full Text] [Related]

  • 4. Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).
    Kristen AV, Maurer MS, Rapezzi C, Mundayat R, Suhr OB, Damy T, THAOS investigators.
    PLoS One; 2017 Nov 10; 12(4):e0173086. PubMed ID: 28384285
    [Abstract] [Full Text] [Related]

  • 5. Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
    Gentile L, Diemberger I, Plante-Bordeneuve V, Mazzeo A, Dori A, Luigetti M, Di Paolantonio A, Dispenzieri A, Grogan M, Waddington Cruz M, Adams D, Inamo J, Kristen AV, Lino Cirami C, Chapman D, Gupta P, Glass O, Amass L.
    PLoS One; 2024 Nov 10; 19(1):e0292435. PubMed ID: 38241252
    [Abstract] [Full Text] [Related]

  • 6. Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update.
    Dispenzieri A, Coelho T, Conceição I, Waddington-Cruz M, Wixner J, Kristen AV, Rapezzi C, Planté-Bordeneuve V, Gonzalez-Moreno J, Maurer MS, Grogan M, Chapman D, Amass L, THAOS investigators.
    Orphanet J Rare Dis; 2022 Jun 18; 17(1):236. PubMed ID: 35717381
    [Abstract] [Full Text] [Related]

  • 7. DISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis.
    Akinboboye O, Shah K, Warner AL, Damy T, Taylor HA, Gollob J, Powell C, Karsten V, Vest J, Maurer MS.
    Amyloid; 2020 Dec 18; 27(4):223-230. PubMed ID: 32456532
    [Abstract] [Full Text] [Related]

  • 8. Counseling Family Members and Monitoring for Evidence of Disease in Asymptomatic Carriers of Amyloid Transthyretin Cardiac Amyloidosis.
    Barker N, Judge DP.
    Am J Cardiol; 2022 Dec 18; 185 Suppl 1():S43-S50. PubMed ID: 36216601
    [Abstract] [Full Text] [Related]

  • 9. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS).
    Damy T, Kristen AV, Suhr OB, Maurer MS, Planté-Bordeneuve V, Yu CR, Ong ML, Coelho T, Rapezzi C, THAOS Investigators.
    Eur Heart J; 2022 Feb 03; 43(5):391-400. PubMed ID: 30938420
    [Abstract] [Full Text] [Related]

  • 10. Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS.
    Caponetti AG, Rapezzi C, Gagliardi C, Milandri A, Dispenzieri A, Kristen AV, Wixner J, Maurer MS, Garcia-Pavia P, Tournev I, Planté-Bordeneuve V, Chapman D, Amass L, THAOS Investigators.
    JACC Heart Fail; 2021 Oct 03; 9(10):736-746. PubMed ID: 34391735
    [Abstract] [Full Text] [Related]

  • 11. Cardiac Involvement in a Patient Cohort With Val30Met Mutation Transthyretin Amyloidosis.
    Ripoll-Vera T, Buades J, Cisneros E, Gómez Y, Núñez J, Raya M.
    Rev Esp Cardiol (Engl Ed); 2019 Jan 03; 72(1):92-94. PubMed ID: 29223374
    [No Abstract] [Full Text] [Related]

  • 12. Racial Differences in Val122Ile-Associated Transthyretin Cardiac Amyloidosis.
    Batra J, Rosenblum H, Cappelli F, Zampieri M, Olivotto I, Griffin JM, Saith SE, Teruya S, De Los Santos J, Argiro A, Burkhoff D, Perfetto F, Maurer MS.
    J Card Fail; 2022 Jun 03; 28(6):950-959. PubMed ID: 34974181
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Frequencies and geographic distributions of genetic mutations in transthyretin- and non-transthyretin-related familial amyloidosis.
    Zhen DB, Swiecicki PL, Zeldenrust SR, Dispenzieri A, Mauermann ML, Gertz MA.
    Clin Genet; 2015 Oct 03; 88(4):396-400. PubMed ID: 25211232
    [Abstract] [Full Text] [Related]

  • 18. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
    Maia LF, Magalhães R, Freitas J, Taipa R, Pires MM, Osório H, Dias D, Pessegueiro H, Correia M, Coelho T.
    J Neurol Neurosurg Psychiatry; 2015 Feb 03; 86(2):159-67. PubMed ID: 25091367
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 61.